AG
ALNY icon

Aperio Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Aperio Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$5.77M Buy
44,387
+2,192
+5% +$293K 0.02% 764
2020
Q3 		$6.14M Buy
42,195
+3,399
+9% +$483K 0.02% 662
2020
Q2 		$5.75M Buy
38,796
+3,927
+11% +$529K 0.02% 682
2020
Q1 		$3.8M Buy
34,869
+2,428
+7% +$280K 0.02% 764
2019
Q4 		$3.74M Buy
32,441
+6,847
+27% +$683K 0.01% 847
2019
Q3 		$2.06M Buy
25,594
+2,489
+11% +$197K 0.01% 1049
2019
Q2 		$1.68M Sell
23,105
-3,706
-14% -$284K 0.01% 1146
2019
Q1 		$2.5M Buy
26,811
+6,234
+30% +$521K 0.01% 947
2018
Q4 		$1.5M Sell
20,577
-2,830
-12% -$218K 0.01% 1104
2018
Q3 		$2.05M Buy
23,407
+2,695
+13% +$271K 0.01% 1052
2018
Q2 		$2.04M Sell
20,712
-3,085
-13% -$306K 0.01% 1018
2018
Q1 		$2.83M Buy
23,797
+2,719
+13% +$351K 0.01% 850
2017
Q4 		$2.68M Buy
21,078
+4,170
+25% +$524K 0.01% 881
2017
Q3 		$1.99M Buy
16,908
+823
+5% +$70.2K 0.01% 942
2017
Q2 		$1.28M Buy
16,085
+1,432
+10% +$91.5K 0.01% 1117
2017
Q1 		$751K Buy
14,653
+6,133
+72% +$283K 0.01% 1305
2016
Q4 		$319K Sell
8,520
-6,406
-43% -$268K ﹤0.01% 1763
2016
Q3 		$1.01M Buy
14,926
+3,139
+27% +$221K 0.01% 1094
2016
Q2 		$654K Sell
11,787
-2,954
-20% -$186K 0.01% 1258
2016
Q1 		$926K Buy
14,741
+8,328
+130% +$554K 0.01% 1079
2015
Q4 		$604K Buy
6,413
+218
+4% +$20.2K 0.01% 1243
2015
Q3 		$498K Buy
6,195
+618
+11% +$68.7K 0.01% 1296
2015
Q2 		$669K Buy
5,577
+2,630
+89% +$314K 0.01% 1170
2015
Q1 		$308K Buy
2,947
+33
+1% +$3.34K ﹤0.01% 1549
2014
Q4 		$283K Buy
+2,914
New +$270K ﹤0.01% 1540

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Aperio Group's ALNY Position: Q4 2020 in Review

Aperio Group increased its Alnylam Pharmaceuticals (ALNY) stake by 5.2% in Q4 2020, buying an estimated $293K and bringing the position to 44,387 shares worth $5.77M. The position accounts for 0.02% of the portfolio, ranked #764.

Aperio Group first reported a position in ALNY in Q4 2014 and has held it in 25 quarters since. The position peaked at $6.14M in Q3 2020. 375 funds tracked by Wall St. Rank hold ALNY as of Q4 2020.

  • Aperio Group held 44,387 shares of Alnylam Pharmaceuticals worth $5.77M as of Q4 2020.
  • Aperio Group bought 2,192 Alnylam Pharmaceuticals shares in Q4 2020, an estimated $293K.
  • Alnylam Pharmaceuticals made up 0.02% of Aperio Group's portfolio in Q4 2020, its #764 holding.
  • Aperio Group first reported a position in Alnylam Pharmaceuticals in Q4 2014 and has held it in 25 quarters since.
  • Aperio Group's Alnylam Pharmaceuticals position peaked at $6.14M in Q3 2020.
  • 375 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.